European Journal of Biomedical and Pharmaceutical Sciences

THE HUMAN MICROBIOME AS A DETERMINANT OF DRUG RESPONSE AND PERSONALIZED MEDICINE

Mrs. Miryala Roopa Rani*, Ms. Gundoju Srilatha, Dr. Madireddy Mamata

ABSTRACT

The human microbiome has emerged as an important determinant of drug response, therapeutic efficacy and treatment-related toxicity. Increasing evidence shows that the trillions of microorganisms inhabiting the human body, particularly those in the gastrointestinal tract, are not passive bystanders but active participants in pharmacology. Through direct enzymatic transformation of xenobiotics, modulation of host metabolic pathways, alteration of immune signaling and production of bioactive metabolites, the microbiome can influence drug absorption, distribution, metabolism and excretion. These interactions help explain why patients receiving the same medicine often exhibit markedly different therapeutic responses and adverse-event profiles. The growing recognition of this variability has placed the microbiome at the centre of precision medicine, which seeks to tailor interventions according to the biological characteristics of each individual (ElRakaiby et al., 2014; Wilson and Nicholson, 2017). In recent years, advances in metagenomics, metatranscriptomics, metaproteomics and metabolomics have enabled increasingly sophisticated characterization of host–microbiome interactions. These tools are providing insight not only into microbial composition but also into microbial function, metabolic potential and ecological dynamics. Such knowledge is expanding the concept of pharmacotherapy beyond host genetics alone and supporting the development of microbiome-informed diagnostics and interventions. Emerging strategies include microbiome profiling to predict treatment response, personalized nutrition plans, selective use of probiotics and prebiotics, fecal microbiota transplantation, and engineered microbial therapeutics. At the same time, major challenges remain, including interindividual variation, methodological inconsistency, limited causal evidence, ethical concerns and regulatory uncertainty (Franzosa et al., 2015; Integrative Human Microbiome Project Research Network, 2019). This chapter examines the biological basis and clinical importance of microbiome–drug interactions and discusses their relevance to precision therapy. It reviews the composition and functional significance of the human microbiome, the major mechanisms through which microbes influence pharmacological outcomes, the contribution of multi-omics technologies, and the therapeutic opportunities emerging from microbiome research. It also addresses current limitations and future directions for integrating microbiome science into routine clinical practice. A better understanding of these interactions may improve treatment efficacy, reduce toxicity and support more rational, individualized healthcare.

Keywords: Microbiome; gut microbiota; drug metabolism; pharmacokinetics; pharmacodynamics; precision medicine; personalized therapy; multi-omics.